Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
1.460
0.00 (0.00%)
At close: Dec 26, 2025, 4:00 PM EST
1.400
-0.060 (-4.11%)
After-hours: Dec 26, 2025, 7:49 PM EST
Genenta Science Employees
Genenta Science had 13 employees as of December 31, 2024. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$785,995
Market Cap
34.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | -1 | -7.14% |
| Dec 31, 2023 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GNTA News
- 8 days ago - Genenta Science Provides Update on CEO Ownership - GlobeNewsWire
- 4 weeks ago - Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - GlobeNewsWire
- 2 months ago - Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating - Seeking Alpha
- 2 months ago - Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production - GlobeNewsWire
- 6 months ago - Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals - GlobeNewsWire
- 8 months ago - Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference - Newsfile Corp
- 8 months ago - Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies - GlobeNewsWire